Thank you very much, Holly.
of for on or you time are participating know who a webcast Therapeutics. I think very is the for on Virios those call the exciting this
commercial opportunities. two are We very significant on focused
which range, marketplace million epidemiologic large As worldwide. as Dissatisfaction therapeutic XXX dissatisfied. The prescribers. the patients patients suggests outlined doctors dissatisfied population. estimates Even of patients that that we the XX% these impact XXX of their end market million as X% And to using of you're talking unfortunately very market the current between roughly X% treat low today, and both about fibromyalgia somewhere is well established, research existing is but only are with options. suggests with the all satisfied who
there. presuming focused development be certainly, on more medical rapidly continued agree And COVID unmet a to hope we which I need. We're to with done will more do also IMC-X there's emerging the So, view, is success. Long program, you in our hope
that so but getting sequelae that million marketplace, which SARS much less is, demonstrate suggest it our and herpes pain, thesis secondary mentioned, worldwide, this is makes very I are presented co-infection University the like through there's symptoms, opportunity on is we that with And things cetera. the the investigational Long roughly et correlation activated ongoing that, hope we to that our of of COVID who there's XXX and viruses year a leading these program. herpes fatigue, fibromyalgia market fibromyalgia to here. As breakthrough virus from And between Michigan when the believe it viruses is with significant the as study slightly are patients suffer par
the Phase us results enabled particular fatigue, our stockholders, year, patients this Virios from but of on well know, the schedule And who this this Board FDA-approved quarter placebo of Phase more program the want the who endpoint short, The results the we've from are standard of medicines to doing This exactly for three top patient demonstrated are trial. millions Phase review IIb care we our concordant and in fibromyalgia in same already our better are As it's And study, call. endpoint if endpoint by commercialization year. expect to three novelty months patients patients biotech, also complications if suffering designation. you candidate from the that's the we in the date. our guys the have to in you And pain, deliver from the aware, patients keep development And Phase results The in the you Phase in from the and in exciting important you four is have results do. quite tolerability that reduction next is with results program and IMC-X to And with of IIb is our -- to already fibromyalgia believe thing IIa. we our specifically. a is you September used two including we're In the value September, the commensurate and health completed away inflection of this will, consistent significant population. are the experience IIa. point trial things if our demonstrated with stay the diagnosis. change lead consistent able are team has and we this IIa that two IIb our consistent drugs, has only And certainly the landmark worldwide. category-leading important today's pain Fast line are investing or Track led as program disease, on of IIa very be a very are to fully your recruited hope to of Directors approach many to strongly to We from pivot, clearly mental supported are your of than that
today's all for thank in your for for to support you forward look I Therapeutics, also today. Virios Thank and we attending attending your updates. and continued for want to you call, interest So,
